5 recruiting, 4 completed, 1 active not recruiting, 1 suspended. 5 Phase 2, 4 Not applicable, 2 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 5 | Recruiting 2, Active not recruiting 1, Suspended 1, Withdrawn 1 |
| Not applicable | 4 | Recruiting 2, Completed 1, Terminated 1 |
| Phase 1 | 2 | Completed 1, Recruiting 1 |
| Phase 3 | 1 | Recruiting 1 |
Follow Metastatic Cancers: new trials by email Literature Review of Metastatic Cancers trials Research Report on Metastatic Cancers
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| e-Motion : Promoting Emotion Regulation in Chronic Cancer Guided Self-Help intervention, Group and Guided Self-Help intervention - Metastatic Cancers, Myeloma Multiple | Not applicable | Recruiting | Université Libre de Bruxelles | 30 | 2025-11-20 | 2025-11-21 |
| A Phase II Study of Adjuvant Immunotherapy Targeting KRAS G12D, KRAS G12V, or TP53 R175H for Participants With Advanced Gastrointestinal Malignancies KRAS TCR-Transduced PBL, Aldesleukin, Fludarabine - Gastrointestinal Carcinoma, Pancreatic Cancer | Phase 2 | Withdrawn | National Cancer Institute (NCI) | 2025-09-09 | 2025-09-11 | |
| Assessing Systemic Treatment and ctDNA Monitoring Efficacy in Metastatic Cancer Patients Using K4Care Testing. Metastatic Cancers | Recruiting | Gene Solutions | 200 | 2025-04-09 | 2025-07-16 | |
| A Study of REC-1245 in Participants With Unresectable, Locally Advanced, or Metastatic Cancer REC-1245 - Unresectable, Locally Advanced | Phase 1 / Phase 2 | Recruiting | Recursion Pharmaceuticals Inc. | 170 | 2024-11-21 | 2026-08-20 |
| Combination Therapy for Cancer Related Fatigue in Patients With Metastatic Cancers Psychoeducational Intervention, Open Label Placebo, Psychoeducational Intervention+Placebo - Metastatic Cancers, Fatigue | Phase 2 / Phase 3 | Recruiting | M.D. Anderson Cancer Center | 240 | 2024-02-16 | 2026-10-19 |
| EXPRESS: EXcePtional RESponSe - Exceptional and Unexpected Response to Targeted Therapies Blood sampling - Metastatic Cancers | Not applicable | Completed | UNICANCER | 182 | 2016-12-01 | 2022-09-07 |
| Organ-Specific Differences in Immunotherapy Response Among Metastatic Cancer Patients Solid Tumors, Metastatic Cancer to Liver | Completed | Wenlong Zhong, MD | 938 | 2016-01-01 | 2026-06-08 | |
| RADVAX: A Stratified Phase I Trial of Pembrolizumab With Hypofractionated Radiotherapy in Patients With Advanced and Metastatic Cancers Pembrolizumab, Radiotherapy - Metastatic Cancers | Phase 1 | Completed | Abramson Cancer Center at Penn Medicine | 59 | 2015-01-08 | 2021-05-12 |
| Phase 2 Study Assessing Secured Access to Vemurafenib for Patients With Tumors Harboring BRAF Genomic Alterations Vemurafenib - Solid Tumors, Hematologic Cancers | Phase 2 | Active not recruiting | UNICANCER | 216 | 2014-10-13 | 2025-08-01 |
| Personalized Oncogenomics (POG) Program of British Columbia Genome sequencing - Metastatic Cancers, Advanced Cancers | Not applicable | Recruiting | British Columbia Cancer Agency | 5000 | 2014-07-01 | 2025-09-22 |
| Vertebral Augmentation and Radiotherapy of Collapse Spinal Metastatic Cancer Vertebroplasty, Radiotherapy - Metastatic Cancers, Multiple Myeloma | Not applicable | Terminated | University of Arizona | 11 | 2013-08-20 | 2018-11-07 |
| Study to Analyze Mutations in V600 BRAF Oncogen in Participants With Metastatic Melanoma Metastatic Cancers | Completed | Hoffmann-La Roche | 264 | 2013-06-01 | 2023-07-03 | |
| Phase II/Pilot Study of 2nd Generation Anti-CEA Designer T Cells in Adenocarcinomas Gene Modified T Cells - Metastatic Cancers | Phase 2 | Suspended | Roger Williams Medical Center | 48 | 2012-10-01 | 2016-06-14 |
Neoplasms (13) · Neoplasm Metastasis (3) · Colorectal Neoplasms (2) · Multiple Myeloma (2) · Brain Neoplasms (1) · Cholangiocarcinoma (1) · Duodenal Neoplasms (1) · Emotional Regulation (1) · Fatigue (1) · Liver Neoplasms (1) · Lung Neoplasms (1) · Lymphoma (1) · Melanoma (1) · Pancreatic Neoplasms (1) · Spinal Fractures (1)
Neoplasms by Histologic Type (5) · Neoplasms by Site (4) · Pathological Conditions, Signs and Symptoms (4) · Hemic and Lymphatic Diseases (3) · Immune System Diseases (3) · Immunoproliferative Disorders (3) · Lymphoproliferative Disorders (3) · Neoplastic Processes (3) · Pathologic Processes (3) · Blood Protein Disorders (2) · Cardiovascular Diseases (2) · Colonic Diseases (2) · Digestive System Diseases (2) · Digestive System Neoplasms (2) · Gastrointestinal Diseases (2)
Radiotherapy (2) · Blood Specimen Collection (1) · Cyclophosphamide (1) · Kyphoplasty (1) · Population Groups (1) · Vemurafenib (1) · Vertebroplasty (1) · aldesleukin (1) · fludarabine (1) · pembrolizumab (1)
UNICANCER (2) · Abramson Cancer Center at Penn Medicine (1) · British Columbia Cancer Agency (1) · Gene Solutions (1) · Hoffmann-La Roche (1) · M.D. Anderson Cancer Center (1) · National Cancer Institute (NCI) (1) · Recursion Pharmaceuticals Inc. (1) · Roger Williams Medical Center (1) · University of Arizona (1) · Université Libre de Bruxelles (1) · Wenlong Zhong, MD (1)
United States (6) · Canada (2) · France (2) · Belgium (1) · China (1) · Spain (1) · Vietnam (1)
Amit Maity, MD, PhD (1) · Florence Lewis, PhD (1) · Isabelle Merckaert, Professor (1) · Janessa J Laskin, MD (1) · Jean-Yves PI Blay, MD (1) · Krisha Howell, MD (1) · Nicholas D Klemen, M.D. (1) · Richard P Junghans, PhD, MD (1) · Sriram Yennu, MD (1)
PMID 28950338, PMID 29092957, PMID 30318516, PMID 30833417, PMID 31160355, PMID 31371350, PMID 31481506, PMID 31907737, PMID 31959346, PMID 35726793
2014 (1)